Page 60 - Read Online

Moghe et al. Hepatoma Res 2018;4:36 I http://dx.doi.org/10.20517/2394-5079.2018.54 Page 9 of 9

2016;65:727-33.
40. Ravi S, Axley P, Jones D, Kodali S, Simpson H, McGuire BM, Singal AK. Unusually high rates of hepatocellular carcinoma after
treatment with direct-acting antiviral therapy for hepatitis C related cirrhosis. Gastroenterology 2017;152:911-2.
41. ANRS collaborative study group on hepatocellular carcinoma (ANRS CO22 HEPATHER, CO12 CirVir and CO23 CUPILT cohorts).
Lack of evidence of an effect of direct-acting antivirals on the recurrence of hepatocellular carcinoma: data from three ANRS cohorts. J
Hepatol 2016;65:734-40.
42. Kanwal F, Kramer J, Asch SM, Chayanupatkul M, Cao Y, El-Serag HB. Risk of hepatocellular cancer in HCV patients treated with
direct-acting antiviral agents. Gastroenterology 2017;153:996-1005.e1.
43. Li DK, Ren Y, Shaikh O, Fierer DS, Re VL, Abou-Samra AB, Chung RT, Butt A. The short-term incidence of hepatocellular carcinoma
is not increased after hepatitis C treatment with direct-acting antivirals: an ERCHIVES study. Hepatology 2018;67:2244-53.
44. Llovet JM, Villanueva A. Liver cancer: effect of HCV clearance with direct-acting antiviral agents on HCC. Nat Rev Gastroenterol
Hepatol 2016;13:561-2.